- Home
- LCTX vs TEAF Comparison
LCTX vs TEAF Comparison
Compare LCTX & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- TEAF
- Stock Information
- Founded
- LCTX 1990
- TEAF 2017
- Country
- LCTX United States
- TEAF United States
- Employees
- LCTX N/A
- TEAF N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- LCTX Health Care
- TEAF Finance
- Exchange
- LCTX Nasdaq
- TEAF Nasdaq
- Market Cap
- LCTX 110.2M
- TEAF 174.8M
- IPO Year
- LCTX N/A
- TEAF N/A
- Fundamental
- Price
- LCTX $0.55
- TEAF $11.95
- Analyst Decision
- LCTX Strong Buy
- TEAF
- Analyst Count
- LCTX 5
- TEAF 0
- Target Price
- LCTX $4.80
- TEAF N/A
- AVG Volume (30 Days)
- LCTX 2.9M
- TEAF 56.1K
- Earning Date
- LCTX 03-06-2025
- TEAF 01-01-0001
- Dividend Yield
- LCTX N/A
- TEAF 9.20%
- EPS Growth
- LCTX N/A
- TEAF N/A
- EPS
- LCTX N/A
- TEAF N/A
- Revenue
- LCTX $8,719,000.00
- TEAF N/A
- Revenue This Year
- LCTX N/A
- TEAF N/A
- Revenue Next Year
- LCTX $41.15
- TEAF N/A
- P/E Ratio
- LCTX N/A
- TEAF N/A
- Revenue Growth
- LCTX N/A
- TEAF N/A
- 52 Week Low
- LCTX $0.48
- TEAF $11.11
- 52 Week High
- LCTX $1.61
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- LCTX 47.26
- TEAF 35.01
- Support Level
- LCTX $0.51
- TEAF $11.84
- Resistance Level
- LCTX $0.60
- TEAF $12.21
- Average True Range (ATR)
- LCTX 0.04
- TEAF 0.13
- MACD
- LCTX 0.01
- TEAF 0.01
- Stochastic Oscillator
- LCTX 53.85
- TEAF 37.04
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.